Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

Grupo de Estudos Multicentricos em Onco-Hematologia311 enrolled

Overview

This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.

The primary aim was observe response rate after 4 induction cycles.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

311

Conditions

Multiple Myeloma Effects of Chemotherapy

Interventions

Bortezomib, cyclophosphamide, thalidomide, dexamethasoneDRUG

Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * multiple myeloma newly diagnose elegible to autologous transplantation Patients submitted to ctd or vcd Myeloma patients newly diagnose \>18yo Exclusion Criteria: * other chemotherapy induction protocol

Outcomes

Primary Outcomes

Response rate better than very good partial response after 4 induction cycles

The primary outcome is to observe the difference response rate between VCD and CTD induction myeloma elegible patient

Time frame: Response rate after induction phase - at the end of cycle 4- (28 days each cycle)- time frame trough study completion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.